Halozyme Therapeutics (HALO) Stock Price, News & Analysis $39.95 -0.20 (-0.50%) (As of 12/8/2023 08:57 PM ET) Add Compare Share Share Today's Range$39.47▼$41.0650-Day Range$33.32▼$40.8652-Week Range$29.85▼$59.40Volume732,900 shsAverage Volume1.18 million shsMarket Capitalization$5.28 billionP/E Ratio21.25Dividend YieldN/APrice Target$52.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Halozyme Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside32.0% Upside$52.73 Price TargetShort InterestBearish5.33% of Float Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment1.40Based on 9 Articles This WeekInsider TradingSelling Shares$756,200 Sold Last QuarterProj. Earnings Growth45.63%From $2.52 to $3.67 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.03 out of 5 starsMedical Sector20th out of 942 stocksBiological Products, Except Diagnostic Industry2nd out of 157 stocks 3.4 Analyst's Opinion Consensus RatingHalozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.73, Halozyme Therapeutics has a forecasted upside of 32.0% from its current price of $39.95.Amount of Analyst CoverageHalozyme Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.33% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Halozyme Therapeutics has recently increased by 5.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHalozyme Therapeutics has received a 65.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Biopharmaceuticals" and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Halozyme Therapeutics is -1.12. Previous Next 3.6 News and Social Media Coverage News SentimentHalozyme Therapeutics has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Halozyme Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows7 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $756,200.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions92.59% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 45.63% in the coming year, from $2.52 to $3.67 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is 21.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 114.73.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is 21.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 118.41.Price to Earnings Growth RatioHalozyme Therapeutics has a PEG Ratio of 0.55. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 31.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Halozyme Therapeutics Stock (NASDAQ:HALO)Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Read More HALO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HALO Stock News HeadlinesDecember 6, 2023 | finance.yahoo.comWhy Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report?November 19, 2023 | finance.yahoo.comHalozyme Therapeutics' (NASDAQ:HALO) 20% CAGR outpaced the company's earnings growth over the same five-year periodDecember 11, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 17, 2023 | finance.yahoo.comInsider Sell Alert: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of ...November 16, 2023 | finance.yahoo.comHalozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia GravisNovember 16, 2023 | finance.yahoo.comCan Halozyme Therapeutics (HALO) Climb 28.72% to Reach the Level Wall Street Analysts Expect?November 16, 2023 | seekingalpha.comHalozyme Q3: Navigating The Ups And Downs Of Its Innovative PathwayNovember 14, 2023 | morningstar.comHalozyme Therapeutics Inc HALODecember 11, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 9, 2023 | seekingalpha.comHalozyme Therapeutics Non-GAAP EPS of $0.75 beats by $0.04, revenue of $216M in-lineNovember 9, 2023 | msn.comHalozyme (HALO) Q3 Earnings Top Estimates, Revenues LagNovember 8, 2023 | finance.yahoo.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | seekingalpha.comHalozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call TranscriptNovember 6, 2023 | finance.yahoo.comCompared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key MetricsNovember 6, 2023 | markets.businessinsider.comHalozyme Therapeutics, Inc. Q3 Profit Increases, beats estimatesNovember 6, 2023 | finance.yahoo.comHALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTSNovember 6, 2023 | finance.yahoo.comHalozyme Therapeutics Inc (HALO) Reports 15% YoY Increase in Q3 Royalty Revenue, Raises 2023 ...November 6, 2023 | finance.yahoo.comHalozyme Therapeutics (HALO) Q3 Earnings Surpass EstimatesNovember 6, 2023 | seekingalpha.comHalozyme Therapeutics, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 6, 2023 | markets.businessinsider.comHalozyme Therapeutics Announces Thirteenth License Partner For ENHANZENovember 6, 2023 | finance.yahoo.comHalozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's DiseaseNovember 5, 2023 | msn.comHalozyme Therapeutics Q3 2023 Earnings PreviewNovember 5, 2023 | markets.businessinsider.comHalozyme Therapeutics earnings: here's what Wall Street expectsOctober 30, 2023 | finance.yahoo.comHalozyme To Report Third Quarter 2023 Financial and Operating ResultsOctober 20, 2023 | msn.comBenchmark Reiterates Halozyme Therapeutics (HALO) Buy RecommendationOctober 20, 2023 | finance.yahoo.com12 Cheap Biotech Stocks Smart Investors Are Piling IntoOctober 20, 2023 | finance.yahoo.comBristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study GoalsSee More Headlines Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/11/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:HALO CUSIP40637H10 CIK1159036 Webwww.halozyme.com Phone858-794-8889Fax858-704-8311Employees393Year Founded1998Price Target and Rating Average Stock Price Target$52.73 High Stock Price Target$66.00 Low Stock Price Target$42.00 Potential Upside/Downside+32.0%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$1.88 Trailing P/E Ratio21.25 Forward P/E Ratio15.85 P/E Growth0.55Net Income$202.13 million Net Margins32.52% Pretax Margin40.72% Return on Equity190.74% Return on Assets16.74% Debt Debt-to-Equity Ratio6.01 Current Ratio7.63 Quick Ratio6.51 Sales & Book Value Annual Sales$660.12 million Price / Sales7.99 Cash Flow$2.58 per share Price / Cash Flow15.48 Book Value$1.26 per share Price / Book31.71Miscellaneous Outstanding Shares132,100,000Free Float128,928,000Market Cap$5.28 billion OptionableOptionable Beta1.25 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Helen I. Torley M.B. Ch. B. (Age 60)M.R.C.P., President, CEO & Director Comp: $1.45MMs. Nicole LaBrosse (Age 40)Senior VP & CFO Comp: $727.04kDr. Michael J. LaBarre Ph.D. (Age 59)Senior VP & Chief Technical Officer Comp: $723.24kMr. Mark Snyder Esq.Chief Legal OfficerMs. Cortney Caudill M.B.A.Chief Operations OfficerMs. Tram BuiHead of Investor Relations & Corporate CommunicationsMs. Amy Marinne FoxChief Human Resources OfficerDr. Steve Knowles MBBSChief Medical OfficerDr. Christopher Bryant Ph.D. (Age 62)Chief Manufacturing Officer & Head of Technical Operations Ms. Kristin SchwartzbauerHead of QualityMore ExecutivesKey CompetitorsChina Biologic ProductsNASDAQ:CBPOMomenta PharmaceuticalsNASDAQ:MNTAExelixisNASDAQ:EXELVaxcyteNASDAQ:PCVXAbcamNASDAQ:ABCMView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 28,958 shares on 12/1/2023Ownership: 0.118%EP Wealth Advisors LLCBought 5,516 shares on 11/24/2023Ownership: 0.004%Aurora Investment CounselBought 35,261 shares on 11/22/2023Ownership: 0.027%Verity Asset Management Inc.Bought 5,741 shares on 11/22/2023Ownership: 0.024%Walleye Trading LLCBought 3,000 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions HALO Stock Analysis - Frequently Asked Questions Should I buy or sell Halozyme Therapeutics stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HALO shares. View HALO analyst ratings or view top-rated stocks. What is Halozyme Therapeutics' stock price target for 2024? 11 equities research analysts have issued twelve-month target prices for Halozyme Therapeutics' shares. Their HALO share price targets range from $42.00 to $66.00. On average, they predict the company's stock price to reach $52.73 in the next twelve months. This suggests a possible upside of 32.0% from the stock's current price. View analysts price targets for HALO or view top-rated stocks among Wall Street analysts. How have HALO shares performed in 2023? Halozyme Therapeutics' stock was trading at $56.90 on January 1st, 2023. Since then, HALO shares have decreased by 29.8% and is now trading at $39.95. View the best growth stocks for 2023 here. Are investors shorting Halozyme Therapeutics? Halozyme Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 6,970,000 shares, an increase of 5.9% from the October 31st total of 6,580,000 shares. Based on an average trading volume of 875,400 shares, the short-interest ratio is presently 8.0 days. Approximately 5.3% of the shares of the company are short sold. View Halozyme Therapeutics' Short Interest. When is Halozyme Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024. View our HALO earnings forecast. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings results on Monday, November, 6th. The biopharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.02. The biopharmaceutical company earned $216.03 million during the quarter, compared to the consensus estimate of $219.47 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 190.74% and a net margin of 32.52%. What ETFs hold Halozyme Therapeutics' stock? ETFs with the largest weight of Halozyme Therapeutics (NASDAQ:HALO) stock in their portfolio include Future Fund Long/Short ETF (FFLS), Future Fund Active ETF (FFND), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), BlackRock Future Innovators ETF (BFTR), Invesco S&P MidCap 400 Pure Growth ETF (RFG), SPDR S&P Biotech ETF (XBI) and Goldman Sachs Future Health Care Equity ETF (GDOC). What guidance has Halozyme Therapeutics issued on next quarter's earnings? Halozyme Therapeutics issued an update on its FY23 earnings guidance on Monday, November, 6th. The company provided EPS guidance of $2.70-$2.80 for the period, compared to the consensus earnings per share estimate of $2.64. The company issued revenue guidance of $825-$845 million, compared to the consensus revenue estimate of $830.22 million. What is Helen Torley's approval rating as Halozyme Therapeutics' CEO? 12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV). Who are Halozyme Therapeutics' major shareholders? Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (5.85%), Northern Trust Corp (1.52%), Charles Schwab Investment Management Inc. (1.29%), Bank of New York Mellon Corp (0.99%), Allspring Global Investments Holdings LLC (0.67%) and Kennedy Capital Management LLC (0.49%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley, Matthew L Posard, Michael J Labarre and Nicole Labrosse. View institutional ownership trends. How do I buy shares of Halozyme Therapeutics? Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Halozyme Therapeutics have any subsidiaries? The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.Read More This page (NASDAQ:HALO) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.